Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management – PubMed
Description
Playback speed:
<button class="mdp-speaker--speed-button" aria-label="0.8x speed" title="0.8x speed" data-speed="0.8">0.8x</button>
<button class="mdp-speaker--speed-button" aria-label="1x speed" title="1x speed" data-speed="1">1x</button>
<button class="mdp-speaker--speed-button" aria-label="1.3x speed" title="1.3x speed" data-speed="1.3">1.3x</button>
<button class="mdp-speaker--speed-button" aria-label="1.6x speed" title="1.6x speed" data-speed="1.6">1.6x</button>
<button class="mdp-speaker--speed-button" aria-label="2x speed" title="2x speed" data-speed="2">2x</button>
Ben Fleming et al.
British Medical Journal.
2023.
Cognitive impairment is a debilitating side effect experienced by patients with cancer treated with systemically administered anticancer therapies. With around 19.3 million new cases of cancer worldwide in 2020 and the five year survival rate growing from 50% in 1970 to 67% in 2013, an urgent need exists to understand enduring side effects with severe implications for quality of life. Whereas cognitive impairment associated with chemotherapy is recognized in patients with breast cancer, researchers have started to identify cognitive impairment associated with other treatments such as immune, endocrine, and targeted therapies only recently. The underlying mechanisms are diverse and therapy specific, so further evaluation is needed to develop effective therapeutic interventions. Drug and non-drug management strategies are emerging that target mechanistic pathways or the cognitive deficits themselves, but they need to be rigorously evaluated. Clinically, consistent use of objective diagnostic tools is necessary for accurate diagnosis and clinical characterization of cognitive impairment in patients treated with anticancer therapies. This should be supplemented with clinical guidelines that could be implemented in daily practice. This review summarizes the recent advances in the mechanisms, clinical characterization, and novel management strategies of cognitive impairment associated with treatment of non-central nervous system cancers.
United States
